SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
European Perspective on the Costs and Cost-Effectiveness of Cancer Therapies
1 references·8 citing·31 second hop
European Perspective on the Costs and Cost-Effectiveness of Cancer Therapies (2007)European Perspective on the Costs and Cos…National Institute for Clinical Excellence and its value judgments (2004)National Institute for Clinic…Cost-Utility Analysis of Cancer Prevention, Treatment, and Control (2015)Cost-Utility Analysis of Canc…Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US (2014)Cancer economics, policy and …Preferences for cancer treatments: an overview of methods and applications in oncology (2012)Preferences for cancer treatm…Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs (2011)Oncogenic Targets, Magnitude …Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia? (2010)Are Cancer Drugs Less Likely …Public funding of new cancer drugs: Is NICE getting nastier? (2009)Public funding of new cancer …Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective (2008)Market and patient access to …An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom (2008)An Economic Evaluation of Cet…Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Cost of Cancer Care: Issues and Implications (2007)The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004 (2008)A systematic review of coverage decision-making on health technologies—Evidence from the real world (2012)Preface (2007)Health systems in transition. (2010)Decision making by NICE: examining the influences of evidence, process and context (2013)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)EuroQol: the current state of play (1996)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)Delivering affordable cancer care in high-income countries (2011)Economic burden of cancer across the European Union: a population-based cost analysis (2013)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Is economic evaluation in touch with society's health values? (2004)Orphan drugs and the NHS: should we value rarity? (2005)Value based pricing for NHS drugs: an opportunity not to be missed? (2008)A New Approach to Consumer Theory (1966)Methods for the Economic Evaluation of Health Care Programmes (2005)Multicriteria decision analysis in oncology (2014)Theory of games and economic behavior (2019)Meta-analysis in clinical trials (1986)Excess in the pharmaceutical industry (2004)How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question (2009)Modeling Valuations for EuroQol Health States (1997)Methods for the economic evaluation of health care programmes, 3rd ed (2006)American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care (2009)Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)The cost‐effectiveness of oral health interventions: A systematic review of cost‐utility analyses (2017)Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions (2019)
this work references cited by second hop

References

  • 2004National Institute for Clinical Excellence and its value judgments767 cited

Cited by

  • 2012Preferences for cancer treatments: an overview of methods and applications in oncology111 cited
  • 2014Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US70 cited
  • 2015Cost-Utility Analysis of Cancer Prevention, Treatment, and Control70 cited
  • 2009Public funding of new cancer drugs: Is NICE getting nastier?68 cited
  • 2011Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs68 cited
  • 2008Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective67 cited
  • 2008An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom63 cited
  • 2010Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?59 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work